-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

4086 Changes in Symptoms, Function, and Quality of Life in Older Adults with Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents

Program: Oral and Poster Abstracts
Session: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III
Hematology Disease Topics & Pathways:
Research, elderly, Clinical Research, patient-reported outcomes, Study Population, Human
Monday, December 12, 2022, 6:00 PM-8:00 PM

Ya-Ning Chan, PhD, RN1*, Daniel R. Richardson, MD, MSc, MA2,3, Courtney Berry, BS, MA, BSN, RN, OCN3*, Stephanie Betancur, BSN, RN1*, Hayden Michael Dumaw, BS4*, Todd Schwartz, DrPH1,4*, Mackenzi Pergolotti, PhD, OTR/L5*, Susan Coppola, MS, OT/L, OTD, FAOTA6*, Christopher Jensen, MD2*, Matthew C. Foster, MD2,3 and Ashley L. Bryant, PhD, RN, OCN, FAAN1

1School of Nursing, University of North Carolina at Chapel Hill, Chapel Hill, NC
2Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC
3Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
4Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC
5Select Medical, ReVital Cancer Rehabilitation, Raleigh, NC
6Department of Health Science, University of North Carolina at Chapel Hill, Chapel Hill, NC


Venetoclax and hypomethylating agents (HMA+VEN), initiated in inpatient or outpatient, is the standard treatment for many older adults (≥60 years) with acute myeloid leukemia (AML). However, little is known about the patient experience of receipt of this regimen in older adults with AML, specifically on their changes in symptoms, function and quality of life (QOL). Hence, this study aims to explore changes in symptoms, function, and QOL during cycle 1 and cycle 2 of HMA+VEN.


This was a preliminary analysis of the control group of an ongoing clinical trial (NCT04570709). Assessments were conducted at cycle 1 and cycle 2 of HMA+VEN. Nineteen AML specific symptoms were measured with the Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE), performance status was assessed using the Clinician-reported Karnofsky Performance Scale (KPS), function and QOL were measured with the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). Descriptive analysis was performed. Specifically, mean±standard deviation was calculated for the KPS and the QLQ-C30; percentage was calculated for the PRO-CTCAE.


A total of 20 (cycle 1) and 15 (cycle 2) participants completed assessments, with an attrition rate of 25%. Attrition reasons included death (n=2) and consent withdrawal due to feeling overwhelmed (n=3). Fifteen out of 20 participants were treated in the outpatient infusion clinic at cycle 1 and all participants received outpatient treatment at cycle 2. Twenty participants (cycle 1) and 14 participants (cycle 2) received treatment at the same institution for both cycles; 1 participant received cycle 2 treatment at their local oncology practice. The mean sample age was 74.65±7.5 (range 64-89 years). Most patients were male (75%), non-Hispanic White (85%), high-school graduate/GED or above (95%), married/partnered (70%), and living with others (65%). Performance status remained stable with 86±18.5 at cycle 1 and 85.48±15.8 at cycle 2. However, between cycles, the score of each function scales (physical: 72.3±22.6, 76.9±18.0; role: 56.7±33.9, 65.6±21.3; emotional: 83.3±15.3, 86.7±10.8; cognitive: 77.5±26.1, 87.8±16.0; social: 60±28.8,75.6±23.5) and overall QOL (55.8±22.6, 64.4±16.8) from the QLQ-C30 increased from cycle 1 to cycle 2. Fatigue was the worst reported symptom (49.4±29.8, 39.3±17.2) among the QLQ-C30 symptoms; 80% and 73% of the sample reported “mild” to “very severe” fatigue/tiredness/lack of energy using the PRO-CTCAE at cycle 1 and cycle 2, respectively. Specifically, among the patients having fatigue symptom, “severe” to “very severe” fatigue/tiredness/lack of energy was only reported at cycle 1 (severe: 15%, 0%; very severe: 10%, 0%); while "mild" to "moderate" fatigue/tiredness/lack of energy was reported at both cycle 1 and cycle 2 (mild: 25%, 40%; moderate: 30%, 33%).


The high severity and prevalence of fatigue highlight the necessity of exploring early interventions at the initiation of cycles to manage symptom and mitigate functional decline. Quality of life increases between cycles may be attributable to the understanding of AML process and initiation of chemotherapy. Further exploration of care settings (inpatient vs outpatient, cancer center vs local oncology practice) at each cycle is needed. Future AML studies warrant an increased female, black, indigenous, and people of color samples to better understand symptom, function, and QOL changes between cycles 1 and 2 of HMA+VEN.

Disclosures: Pergolotti: Select Medical: Current Employment. Foster: Daiichi Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees; LOXO Oncology: Research Funding; Macrogenics: Research Funding; Newave Pharmaceuticals: Research Funding; Rafael Pharmaceuticals: Research Funding; Zentalis Pharmaceuticals: Consultancy; Bellicum Pharmaceuticals: Research Funding. Bryant: Carevive Systems, Inc: Research Funding.

*signifies non-member of ASH